The question is, who pays?
The European Union has some 20 "biosimilar" generics on the market; the US has one.
Drug makers are raising concerns Brexit could delay regulatory approval, slow down funding for basic research
Investors' demands for more profits left patients with the choice to pay up or die.
Some manufacturers are willing to tie drug price to performance.
FTC files case against drug maker for deals cut with two generic firms that extend its monopoly
The company's CEO stepped down on Monday
We'd pay a lot more if it wasn’t for generics, which amount to as much as 85% of what we take.
Valeant and a handful other firms may ditch a model that's come under fire.
A new report suggests drug makers are profiting from the waste.